The survival time of patients with hilar lymph node metastasis is related to the severity of the disease and the patient’s physical quality, and cannot be accurately judged, so it is recommended to actively accept treatment. After the emergence of hilar lymph node metastasis, radiotherapy, chemotherapy, targeted therapy, immunotherapy and other comprehensive treatments can be used to inhibit the proliferation of the tumor, reduce the tumor foci, improve the quality of life of the patient, prolong the survival time of the patient, and improve the prognosis of the disease. The chemotherapeutic drugs that patients can choose from include paclitaxel, cyclophosphamide, cisplatin and so on. Targeted drugs include bevacizumab, cetuximab, and so on. Due to individual differences, there is no absolute most effective drug, need to be standardized under the guidance of the doctor, adverse reactions such as bloating, nausea, etc. should consult a doctor in a timely manner, drug allergy is prohibited. By actively cooperating with the doctor to receive standardized treatment, can effectively extend the patient’s survival time, improve the prognosis of the disease.